>About VOHC
>Veterinary Staff
>Technical Staff
>Our Facilities
>Clinical Trials
>FAQs
>Animal Cancer Foundation
>Contact Us
>Directions
Clinical Trials
Clinical trials are programs that allow researchers to study the effects of new “experimental” treatment options, with the hope of finding new and improved ways to treat cancer. There may be a clinical trial available for your pet to join either instead of more traditional treatment, or in the case of those traditional treatments failing.

Clinical trials help researchers figure out if new treatment options are safe and effective, whether there are any side effects or risks to the patient, and whether the new treatment is potentially better than existing options.

Advantages to allowing your pet participate in a clinical trial include receiving a new drug before it is widely available – potentially at decreased or no cost to you. Also, since many cancers in animals similarly occur in humans, you and your pet may be helping to pave the way for successful treatment methods that benefit both animals as well as humans.

Disadvantages exist because of the experimental nature of the treatment – although the effectiveness must first be proven in laboratory animals, there is a possibility of unexpected side effects to your pet. You will always reserve the right to remove your pet from a clinical trial at any point if you would like to pursue other avenues of treatment.

Please feel free to talk to any of our doctors to find out about any new clinical trials that may be available to your pet or how to participate in any of the studies listed below.
 
Current Clinical Trials - Conducted at VOHC
Trial Description
Masitinib in dogs

We are excited to offer inclusions in 6 open label clinical studies with masitinib oral route in the following indications:
   • All cancers - combination masitinib/vinblastin
   • All cancers - combination masitinib/gemcitabin
   • Splenic hemangiosarcoma (dogs naïve of treatment) - masitinib, doxorubicin, combination masitinib/doxorubicin
   • T cell lymphoma (dogs naïve of treatment) - masitinib, doxorubicin, combination masitinib/doxorubicin
   • Melanoma (dogs naïve of treatment) - combination masitinib/doxorubicin, vaccine
   • Melanoma expressing mutated c-kit (dogs naïve of treatment) - masitinib, vaccine

Masitinib is a registered therapy in Europe to treat unresectable Mast Cell Tumors in dogs. Masitinib is a Tyrosine Kinase Inhibitor that selectively inhibits c-kit, PDGFr and Lyn.

Main exclusion criteria are: Dogs less than 6 months of age or weighing less than 3.5 kg (7.7 lb), with cardiac insufficiency, evidence of gastric bleeding, other serious disease or prior history of kidney disease.

Trial Support/Funding Includes: The studies are partially funded.

For more details: Please contact Maria Salas or Dr. Gerald Post at 203-838-6626. 

Click here to download a PDF file with the above and more information.

HOME  |  DIRECTIONS  |  CONTACT US  |  REFERRING VETS  |  SITE MAP
©2006 Veterinary Oncology & Hematology Center, LLC. Last updated 12/12/2007
Site Designed by One Brain Marketing, LLC. Hosted by Advanced Web Systems
“Smokey taught me the value of leaving no stone unturned in the search for better therapies and
the importance of hope.”
               - Dr Gerald Post
> Smokey's Story
> Other Success Stories